Study of INBRX-106 and INBRX-106 in Combination With Pembrolizumab (Keytruda®) in Subjects With Locally Advanced or Metastatic Solid Tumors (Hexavalent OX40 Agonist)

Active:	Yes
Cancer Type:	Lung Cancer Melanoma Stomach/ Gastric Cancer	NCT ID:	NCT04198766
Trial Phases:	Phase I Phase II	Protocol IDs:	Ph 1 INBRX-106 (primary) NCI-2020-06313 MK3475 KEYNOTE A99
Eligibility:	18 Years and older, Male and Female	Study Type:	Treatment
Study Sponsor:	Inhibrx Biosciences, Inc
NCI Full Details:	http://clinicaltrials.gov/show/NCT04198766

Summary

This is a Phase 1/2, open-label, non-randomized, 4-part trial to determine the safety
profile and identify the maximum tolerated dose (MTD) and/or recommended Phase 2 dose
(RP2D) of INBRX 106 administered as a single agent or in combination with the anti-PD-1
checkpoint inhibitor (CPI) pembrolizumab (Keytruda®). KEYTRUDA is a registered trademark
of Merck Sharp & Dohme LLC, a subsidiary of Merck & Co., Inc., Rahway, NJ, USA.

Treatment Sites in Georgia

Winship Cancer Institute of Emory University
1365 Clifton Road NE
Building C
Atlanta, GA 30322
winshipcancer.emory.edu

**Clinical trials are research studies that involve people. These studies test new ways to prevent, detect, diagnose, or treat diseases. People who take part in cancer clinical trials have an opportunity to contribute to scientists’ knowledge about cancer and to help in the development of improved cancer treatments. They also receive state-of-the-art care from cancer experts... Click here to learn more about clinical trials.